- Home
- / Deciphera Pharmaceuticals
- / Financials
Header placeholder lorem ipsum dolor sit amet, consectetur adipiscing elit.
Deciphera Pharmaceuticals financials data including stock price, CreditSafe score, income statement, balance sheet, and cash flow.
Stock Price
$25.6
2024-06-10
Market Capitalization
$2.2 B
2024-06-10
Revenue
$163.4 M
FY, 2023
CreditSafe Score
?
Score changed on Jun 13, 2026
Premium Content only available in Craft’s Intelligence Portal
View 30+ financial ratio metrics including price-to-earnings ratio, debt-to-assets ratio, gross profit margin, and more.
Financial ratio metrics help evaluate the financial strength of a company, and help raise red flags that can indicate potential risk, fulfillment challenges, or even possible bankruptcy.
Learn moreFinancial Statements
| USD | FY, 2015 | FY, 2016 | FY, 2017 | FY, 2018 | FY, 2019 | FY, 2020 | FY, 2021 | FY, 2022 | FY, 2023 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 25.0M | 42.1M | 96.1M | 134.0M | 163.4M | ||||
| Cost of goods sold | 225.0K | 2.9M | 8.8M | 3.7M | |||||
| Gross profit | 41.9M | 93.2M | 125.3M | 159.6M | |||||
| Gross profit margin, % | 99.5% | 97.0% | 93.5% | 97.7% | |||||
| General and administrative expense | 5.1M | 5.7M | 11.4M | 21.2M | 68.1M | 114.1M | 136.3M | 120.2M | 136.5M |
| Operating expense total | 17.6M | 25.8M | 50.9M | 104.1M | 225.7M | 313.1M | 393.3M | 308.0M | 370.6M |
| EBIT | (17.6M) | (25.8M) | (50.9M) | (104.1M) | (200.7M) | (271.2M) | (300.1M) | (182.7M) | (211.0M) |
| EBIT margin, % | -802.9% | -644.4% | -312.1% | -136.3% | -129.1% | ||||
| Interest income | 16.7M | ||||||||
| Interest expense | 2.2M | 106.0K | 95.0K | 84.0K | 67.0K | ||||
| Pre tax profit | (300.0M) | (178.2M) | (194.5M) | ||||||
| Income tax expense | 431.0K | ||||||||
| Net Income | (19.8M) | (25.9M) | (50.3M) | (99.9M) | (192.3M) | (266.5M) | (300.0M) | (178.9M) | (194.9M) |
| EPS | (2.4) | (2.3) |